Prognosis and Risk Factors for Non-Response to Chemoimmunotherapy in Esophageal Cancer

253 patients with locally advanced esophageal squamous cell carcinoma treated between 2020 and 2023. The dataset, authored by Jun-Peng Lin, analyzes pathological non-response rates and associated survival outcomes. It identifies lymphovascular and perineural invasion as key risk factors.

Use Cases

• Predict pathological non-response to neoadjuvant chemoimmunotherapy based on clinical and pathological features.
• Model survival outcomes (OS/DFS) for patients with esophageal squamous cell carcinoma.
• Identify high-risk subgroups within non-responders based on perineural invasion and nodal stage.
• Analyze recurrence patterns (locoregional vs. distant) following treatment.

Strengths

• Includes 253 patient records with defined treatment and outcome criteria.
• Provides specific survival statistics: 3-year OS of 58.2% vs. 75.8% for non-responders vs. responders.
• Identifies concrete risk factors (LVI, PNI) with statistical significance (P<0.001).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect temporal bias inherent to the 2020-2023 collection period.

Provenance

Source

figshare

Collection Method

Retrospective analysis of patients receiving neoadjuvant chemoimmunotherapy followed by surgery.

Time Range

2020 to 2023

Freshness

Last updated 2026-04-29 05:57:34.